Squamous overgrowth is not a safety concern for photodynamic therapy for Barrett's esophagus with high-grade dysplasia.
Bronner, Mary P; Overholt, Bergein F; Taylor, Shari L; Haggitt, Rodger C; Wang, Kenneth K; Burdick, J Steven; Lightdale, Charles J; Kimmey, Michael; Nava, Hector R; Sivak, Michael V; Nishioka, Norman; Barr, Hugh; Canto, Marcia I; Marcon, Norman; Pedrosa, Marcos; Grace, Michael; Depot, Michelle.
; 136(1): 2017 Apr; quiz 351-2, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18996379
Photodynamic therapy for Barrett's esophagus with high-grade dysplasia.
A randomised controlled trial of ALA vs. Photofrin photodynamic therapy for high-grade dysplasia arising in Barrett's oesophagus.
Comparison of endoscopic treatment modalities for Barrett's neoplasia.
The dose of omeprazole required to achieve adequate intraesophageal acid suppression in patients with gastroesophageal junction specialized intestinal metaplasia and Barrett's esophagus.
Long-term outcomes of the randomized controlled trial comparing 5-aminolaevulinic acid and Photofrin photodynamic therapy for Barrett's oesophagus related neoplasia.
Role of acid suppression in the development and progression of dysplasia in patients with Barrett's esophagus.
Residual embryonic cells as precursors of a Barrett's-like metaplasia.
Management of Barrett's esophagus.
Whole slide image cytometry: a novel method to detect abnormal DNA content in Barrett's esophagus.
Esófago de Barrett: experiencia de 10 años en un centro de tercer nivel en México.